Last €223.42 EUR
Change Today -4.13 / -1.82%
Volume 5.3K
RHO On Other Exchanges
Symbol
Exchange
OTC US
OTC US
OTC US
Xetra
SIX Swiss Ex
Xetra
SIX Swiss Ex
Mexico
Frankfurt
As of 3:19 PM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-br (RHO) Snapshot

Open
€226.84
Previous Close
€227.56
Day High
€229.75
Day Low
€223.42
52 Week High
12/8/14 - €242.50
52 Week Low
01/30/14 - €191.47
Market Cap
194.1B
Average Volume 10 Days
4.7K
EPS TTM
--
Shares Outstanding
160.0M
EX-Date
03/6/14
P/E TM
--
Dividend
€7.68
Dividend Yield
2.86%
Current Stock Chart for ROCHE HOLDING AG-BR (RHO)

roche holding ag-br (RHO) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate for treating non-small-cell lung cancer; and a collaboration agreement with AmorChem L.P. to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 or Steinert's disease. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holding ag-br (RHO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holding ag-br (RHO) Key Developments

Roche to Discontinue Phase III Study of Gantenerumab in Early Alzheimer’s Disease

Roche has announced its plans to discontinue SCarlet RoAD (WN25203), a Phase III study of investigational anti-amyloid medicine gantenerumab in prodromal (pre-dementia) Alzheimer's disease. Gantenerumab (RG1450) is a fully human, monoclonal antibody designed to decrease levels of beta amyloid, a protein that accumulates in the brains of people with Alzheimer's disease. The decision was based as per the recommendation by the independent Data Monitoring Committee and on the results of a pre-planned futility analysis, which found no new safety signals for gantenerumab. The investigational drug also showed a similar overall safety profile as observed in the Phase I trial (NN19866). However, gantenerumab will be evaluated by Roche in the Phase III Marguerite RoAD study (WN28745) in a later stage of Alzheimer's disease or mild dementia. Furthermore, the company's two investigational medicines, an anti-amyloid antibody crenezumab and a monoamine oxidase-B inhibitor RG1577, are currently in Phase II development for the disease.

Roche Launches Next-Generation Viral Load Testing Assays for New Molecular Diagnostic Platforms in Markets Accepting the CE Mark

Roche announced the commercial availability of the cobas HIV1 and cobas HCV assays for use on the cobas 6800/8800 Systems--expanding the menu on the newest molecular diagnostic platforms from Roche with next generation viral load monitoring assays. The new assays offer the high performance that clinicians depend on to manage the treatment of patients infected with Human Immunodeficiency Virus (HIV1) or Hepatitis C (HCV). The assays launched will be followed in the coming months by the cobas CMV and cobas HBV assays, which will complete the primary portfolio of viral load monitoring assays for the cobas 6800/8800 Systems. This viral load portfolio on the cobas 6800/8800 Systems will provide laboratories with improved productivity and the ability to deliver results for rapid clinical decisions. The cobas HIV1 and HCV assays and the cobas 6800/8800 Systems are commercially available in markets that recognize CEMark and are not currently available in the United States.

TTPH Reportedly Explores Options For Sale

Tetraphase Pharmaceuticals, Inc. (NasdaqGS:TTPH) is exploring a sale after attracting interest from potential buyers, people familiar with the matter said. TTPH is working with advisers to explore its options, the people said, asking not to be identified because the deliberations are private. TTPH may attract interest from bidders including Actelion Ltd. (SWX:ATLN) and Roche Holding AG (SWX:ROG), the people said. A spokesman for Tetraphase declined to comment. Representatives for Actelion and Roche couldn’t immediately be reached to comment outside of normal business hours.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHO:GR €223.42 EUR -4.13

RHO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.21 USD +1.86
Bayer AG €114.86 EUR -0.61
General Electric Co $25.83 USD -0.05
Gilead Sciences Inc $91.29 USD +1.84
Merck & Co Inc $57.46 USD +0.25
View Industry Companies
 

Industry Analysis

RHO

Industry Average

Valuation RHO Industry Range
Price/Earnings 19.8x
Price/Sales 4.3x
Price/Book 12.0x
Price/Cash Flow 16.1x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-BR, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.